Caligan Partners LP
SEC CIK 1727492 · EDGAR
BoughtSold
Most active insiders at LQDA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bloch Stephen M | Dir | — | $118.66M |
| 2 | JEFFS ROGER | CEO, Dir | — | $31.72M |
| 3 | Kaseta Michael | CFO, COO | — | $15.97M |
| 4 | Manning Paul B | Dir | — | $12.78M |
| 5 | Saggar Rajeev | Chief Medical Off | — | $11.16M |
| 6 | Adair Jason | Chief Business Off | — | $7.77M |
| 7 | Moomaw Scott | Chief Commercial Off | — | $5.52M |
| 8 | Rielly-Gauvin Katherine | Dir | — | $4.09M |
| 9 | Krepp Sarah | Chief Human Resource Off | — | $3.69M |
| 10 | SINGH RAMAN | Dir | — | $3.67M |
| 14 | Caligan Partners LP | Dir, 10%, See Remarks | $317.9K | $317.9K |
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-05-20 20:51 | 2026-05-19 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | S - Sale | $59.98 | -5,300 | 8.13M | -0.1% | -$317.9K |
| I | 2026-05-20 20:51 | 2026-05-19 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | P - Purchase | $59.98 | +5,300 | 8.14M | +0.1% | +$317.9K |
| I | 2025-11-26 | 2025-11-25 | EXEL | EXELIXIS, INC. | Caligan Partners LP | Dir, See Remarks | P - Purchase | $43.12 | +27.5K | 1.55M | +2% | +$1.19M |
| I | 2024-09-12 | 2024-09-12 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | A - Grant | $8.90 | +1.12M | 8.12M | +16% | +$10.00M |
| I | 2024-09-04 | 2024-08-30 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | S - Sale | $9.51 | -150.0K | 6.84M | -2% | -$1.43M |
| I | 2024-09-04 | 2024-08-30 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | P - Purchase | $9.51 | +150.0K | 6.99M | +2% | +$1.43M |
| I | 2024-09-04 | 2024-08-30 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | J - Other | — | -3.44M | 6.99M | -33% | — |
| 2024-06-24 | 2024-06-20 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | A - Grant | $0.00 | +20.4K | 20.4K | New | $0 | |
| I | 2024-02-22 | 2024-02-21 | EXEL | EXELIXIS, INC. | Caligan Partners LP | Dir, See Remarks | P - Purchase | $20.70 | +190.0K | 1.10M | +21% | +$3.93M |
| I | 2023-12-14 | 2023-12-14 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | P - Purchase | $7.16 | +1.12M | 11.28M | +11% | +$8.00M |
| I | 2023-11-29 | 2023-11-27 | EXEL | EXELIXIS, INC. | Caligan Partners LP | Dir | S - Sale | $21.61 | -120.4K | 790.3K | -13% | -$2.60M |
| I | 2023-11-29 | 2023-11-27 | EXEL | EXELIXIS, INC. | Caligan Partners LP | Dir | P - Purchase | $21.61 | +120.4K | 910.7K | +15% | +$2.60M |
| D | 2023-06-02 | 2023-05-31 | EXEL | EXELIXIS, INC. | Caligan Partners LP | Dir, See Remarks | A - Grant | $0.00 | +18.2K | 18.2K | New | $0 |
| I | 2022-12-30 | 2022-12-29 | LAB | STANDARD BIOTOOLS INC. | Caligan Partners LP | 10% | J - Other | — | -2.87M | 8.58M | -25% | — |
| I | 2022-06-15 | 2022-06-13 | LAB | STANDARD BIOTOOLS INC. | Caligan Partners LP | 10%, See Remarks | P - Purchase | $1.70 | +100.0K | 10.52M | +1.0% | +$170.0K |
| I | 2022-05-26 | 2022-05-25 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | P - Purchase | $3.40 | +79.4K | 10.39M | +0.8% | +$270.0K |
| MI | 2022-05-19 | 2022-05-17+ | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | P - Purchase | $5.89 | +221.1K | 10.15M | +2% | +$1.30M |
| MI | 2022-05-10 | 2022-05-06+ | LAB | STANDARD BIOTOOLS INC. | Caligan Partners LP | 10% | P - Purchase | $2.88 | +488.4K | 9.95M | +5% | +$1.41M |
| I | 2022-04-18 | 2022-04-18 | LQDA | Liquidia Corp | Caligan Partners LP | Dir, 10%, See Remarks | P - Purchase | $5.10 | +1.76M | 10.09M | +21% | +$9.00M |
| MI | 2022-04-13 | 2022-04-11+ | LAB | STANDARD BIOTOOLS INC. | Caligan Partners LP | 10% | P - Purchase | $3.80 | +195.0K | 9.03M | +2% | +$741.1K |
| MI | 2022-04-08 | 2022-04-06+ | LAB | STANDARD BIOTOOLS INC. | Caligan Partners LP | 10% | P - Purchase | $3.77 | +509.6K | 8.69M | +6% | +$1.92M |
Purchase Sale Sale after option exercise All abbreviations